Prevalence of Hidradenitis Suppurativa in the Netherlands: A Cross-Sectional Study as Part of the Global Hidradenitis Suppurativa Atlas (GHiSA)
Dermatology · 2025
DOI: 10.1159/000542816 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Dermatology, 2025. Verfasst von Johanna C van Huijstee und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Erasmus Medical Centre, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The global prevalence of the chronic and debilitating skin disease hidradenitis suppurativa (HS) is currently unknown. Depending on the research type and the studied population, reported prevalence rates for HS range from 0.03% to 4.1%. It is crucial to investigate the global prevalence of HS using a standardized study design to facilitate earlier recognition, diagnosis, and treatment of patients. Consequently, a worldwide initiative, the Global Hidradenitis Suppurativa Atlas (GHiSA), has developed a study design to investigate the worldwide prevalence of HS in a comparable manner. In cooperation with this initiative, this study aimed to investigate the prevalence of HS in the Netherlands.
Methods
An explorative, descriptive, cross-sectional mono-center study was conducted at the Ear Nose Throat and Internal Medicine department of the Erasmus Medical Center. Healthy adults accompanying patients undergoing care in a hospital setting were asked to fill out a validated questionnaire and undergo physical examination. Primary outcome was the point prevalence of HS.
Results
In total, 663 participants were included in this study. Overall, the prevalence of HS was 0.60% (4/663, 95% confidence interval 0.32%–1.54%).
Conclusion
The point prevalence of HS in the Netherlands is 0.60%. This study is part of a global initiative; therefore, data can be incorporated in a worldwide analysis of the HS prevalence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Erasmus Medical Centre, Rotterdam, The Netherlands.
- Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
- Department of Clinical Medicine, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark.
- Section for Biostatistics and Evidence-Based Research, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
- Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark.
- Cochrane Denmark and Centre for Evidence-Based Medicine Odense (CEBMO), Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Zitieren
APA
van Huijstee, J. C., van Straalen, K. R., Bouazzi, D., Medianfar, C. E., Jemec, G. B. E., Christensen, R., Aarts, P., Mangal, R. A., Erdal, B., Geraedts, N. C. T., Prens, E. P., & van der Zee, H. H. (2025). Prevalence of Hidradenitis Suppurativa in the Netherlands: A Cross-Sectional Study as Part of the Global Hidradenitis Suppurativa Atlas (GHiSA). Dermatology. https://doi.org/10.1159/000542816
Vancouver
van Huijstee JC, van Straalen KR, Bouazzi D, Medianfar CE, Jemec GBE, Christensen R, et al. Prevalence of Hidradenitis Suppurativa in the Netherlands: A Cross-Sectional Study as Part of the Global Hidradenitis Suppurativa Atlas (GHiSA). Dermatology. 2025. doi:10.1159/000542816
BibTeX
@article{vanHuijstee2025,
author = {van Huijstee, Johanna C and van Straalen, Kelsey R and Bouazzi, Dorra and Medianfar, Cecilia E and Jemec, Gregor B E and Christensen, Robin and Aarts, Pim and Mangal, Raveena A and Erdal, Beyza and Geraedts, Nienke C T and Prens, Errol P and van der Zee, Hessel H},
title = {Prevalence of Hidradenitis Suppurativa in the Netherlands: A Cross-Sectional Study as Part of the Global Hidradenitis Suppurativa Atlas (GHiSA)},
journal = {Dermatology},
year = {2025},
doi = {10.1159/000542816}
}
EUVIMED